EcoDrugPlus

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSBTAG00000003132
Gene Symbol: CHRNB4
12 Enzyme and pathways 5 Cross references
211 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 7

Ensembl ID : ENSBTAG00000015775
Gene Symbol: CHRNA7
6 Enzyme and pathways 4 Cross references
261 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSBTAG00000020199
Gene Symbol: F2R
12 Enzyme and pathways 5 Cross references
344 Possible Orthologues:

Coagulation Factor Ii, Thrombin

Ensembl ID : ENSBTAG00000007148
Gene Symbol: F2
26 Enzyme and pathways 5 Cross references
98 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSBTAG00000007101
Gene Symbol: F3
3 Enzyme and pathways 5 Cross references
257 Possible Orthologues:

Coagulation Factor Vii

Ensembl ID : ENSBTAG00000007411
Gene Symbol: F7
10 Enzyme and pathways 5 Cross references
215 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSBTAG00000016385
Gene Symbol: F10
12 Enzyme and pathways 5 Cross references
251 Possible Orthologues:

Coagulation Factor Xi

Ensembl ID : ENSBTAG00000003572
Gene Symbol: F11
3 Enzyme and pathways 5 Cross references
227 Possible Orthologues:

Coagulation Factor Xii

Ensembl ID : ENSBTAG00000018872
Gene Symbol: F12
3 Enzyme and pathways 5 Cross references
199 Possible Orthologues:

Coiled-Coil Domain Containing 6

Ensembl ID : ENSBTAG00000003189
Gene Symbol: CCDC6
5 Cross references
235 Possible Orthologues:

Colony Stimulating Factor 1 Receptor

Ensembl ID : ENSBTAG00000012771
Gene Symbol: CSF1R
4 Enzyme and pathways 5 Cross references
285 Possible Orthologues:

Complement C1s

Ensembl ID : ENSBTAG00000004840
Gene Symbol: C1S
7 Enzyme and pathways 5 Cross references
200 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).